DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 15470.0
(0.06%)
KRW 15470.0
(0.06%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 138.34 Billion KRW | 15.14% |
| 2022 | 120.15 Billion KRW | 17.12% |
| 2021 | 102.59 Billion KRW | 29.78% |
| 2020 | 79.04 Billion KRW | 29.87% |
| 2019 | 60.86 Billion KRW | -4.16% |
| 2018 | 63.51 Billion KRW | 25.26% |
| 2017 | 50.7 Billion KRW | 12.07% |
| 2016 | 45.24 Billion KRW | 39.12% |
| 2015 | 32.52 Billion KRW | 3.35% |
| 2014 | 31.46 Billion KRW | -3.58% |
| 2013 | 32.63 Billion KRW | 20.88% |
| 2012 | 26.99 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 160.66 Billion KRW | 9.25% |
| 2024 Q1 | 147.05 Billion KRW | 6.3% |
| 2023 Q3 | 137.6 Billion KRW | 6.84% |
| 2023 Q4 | 138.34 Billion KRW | 0.54% |
| 2023 FY | 138.34 Billion KRW | 15.14% |
| 2023 Q1 | 119.61 Billion KRW | -0.44% |
| 2023 Q2 | 128.79 Billion KRW | 7.67% |
| 2022 Q1 | 106.86 Billion KRW | 4.17% |
| 2022 Q3 | 119.58 Billion KRW | 9.08% |
| 2022 Q2 | 109.62 Billion KRW | 2.58% |
| 2022 FY | 120.15 Billion KRW | 17.12% |
| 2022 Q4 | 120.15 Billion KRW | 0.48% |
| 2021 Q4 | 102.59 Billion KRW | 10.89% |
| 2021 Q1 | 88.28 Billion KRW | 11.69% |
| 2021 FY | 102.59 Billion KRW | 29.78% |
| 2021 Q2 | 92.09 Billion KRW | 4.31% |
| 2021 Q3 | 92.51 Billion KRW | 0.46% |
| 2020 Q4 | 79.04 Billion KRW | -5.09% |
| 2020 Q3 | 83.29 Billion KRW | 0.71% |
| 2020 FY | 79.04 Billion KRW | 29.87% |
| 2020 Q1 | 69.72 Billion KRW | 14.55% |
| 2020 Q2 | 82.7 Billion KRW | 18.61% |
| 2019 Q4 | 60.86 Billion KRW | -5.0% |
| 2019 Q1 | 67.33 Billion KRW | 6.02% |
| 2019 Q2 | 68.06 Billion KRW | 1.09% |
| 2019 Q3 | 64.07 Billion KRW | -5.87% |
| 2019 FY | 60.86 Billion KRW | -4.16% |
| 2018 Q2 | 54.28 Billion KRW | 1.78% |
| 2018 FY | 63.51 Billion KRW | 25.26% |
| 2018 Q4 | 63.51 Billion KRW | 2.91% |
| 2018 Q3 | 61.71 Billion KRW | 13.7% |
| 2018 Q1 | 53.33 Billion KRW | 5.19% |
| 2017 Q4 | 50.7 Billion KRW | -4.19% |
| 2017 FY | 50.7 Billion KRW | 12.07% |
| 2017 Q1 | 43.33 Billion KRW | -4.22% |
| 2017 Q2 | 47.15 Billion KRW | 8.81% |
| 2017 Q3 | 52.91 Billion KRW | 12.23% |
| 2016 Q2 | 44.2 Billion KRW | 16.69% |
| 2016 FY | 45.24 Billion KRW | 39.12% |
| 2016 Q1 | 37.88 Billion KRW | 16.48% |
| 2016 Q3 | 47.13 Billion KRW | 6.64% |
| 2016 Q4 | 45.24 Billion KRW | -4.02% |
| 2015 Q2 | 36.52 Billion KRW | 7.14% |
| 2015 FY | 32.52 Billion KRW | 3.35% |
| 2015 Q3 | 34.58 Billion KRW | -5.3% |
| 2015 Q1 | 34.09 Billion KRW | 8.35% |
| 2015 Q4 | 32.52 Billion KRW | -5.98% |
| 2014 FY | 31.46 Billion KRW | -3.58% |
| 2014 Q1 | 33.63 Billion KRW | 3.07% |
| 2014 Q3 | 31.83 Billion KRW | -7.52% |
| 2014 Q2 | 34.42 Billion KRW | 2.35% |
| 2014 Q4 | 31.46 Billion KRW | -1.17% |
| 2013 Q3 | 30.21 Billion KRW | 3.69% |
| 2013 FY | 32.63 Billion KRW | 20.88% |
| 2013 Q2 | 29.14 Billion KRW | 8.36% |
| 2013 Q4 | 32.63 Billion KRW | 7.99% |
| 2013 Q1 | 26.89 Billion KRW | -0.38% |
| 2012 FY | 26.99 Billion KRW | 0.0% |
| 2012 Q3 | 26 Billion KRW | 0.0% |
| 2012 Q4 | 26.99 Billion KRW | 3.84% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 20.85 Billion KRW | -563.259% |
| CMG Pharmaceutical Co., Ltd. | 15.87 Billion KRW | -771.411% |
| Celltrion Pharm, Inc. | 100.42 Billion KRW | -37.764% |
| Huons Global Co., Ltd. | 121.81 Billion KRW | -13.565% |
| Enzychem Lifesciences Corporation | 14.94 Billion KRW | -825.629% |
| Humedix Co., Ltd. | 28.62 Billion KRW | -383.29% |
| Boditech Med Inc. | 31.6 Billion KRW | -337.754% |
| EuBiologics Co., Ltd. | 13.34 Billion KRW | -936.937% |
| FutureChem Co.,Ltd | 1.37 Billion KRW | -9964.953% |
| Huons Co., Ltd. | 76.59 Billion KRW | -80.609% |
| BNC Korea Co., Ltd. | 11.39 Billion KRW | -1114.232% |
| AptaBio Therapeutics Inc. | - KRW | -Infinity% |